Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualizing Pharmacotherapy for Smoking Cessation in African Americans
NCT03897439Phase 3Completed
- Sponsor
- University of Kansas Medical Center
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of varenicline + nicotine patch and bupropion in nicotine dependence (2 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Biochemically Verified Smoking Abstinence at 12 weeks. Started May 2019; status: completed.
02
Drugs
varenicline + nicotine patchbupropion
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03897439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897439.